All lobbying filings

Empire Consulting Group

Empire Consulting Group filed a Q3 report for Amgen Inc. on October 19, 2026, reporting $50,000 in lobbying income.

Lobbying for Amgen Inc. · Healthcare/Biotechnology

As filed: EMPIRE CONSULTING GROUP for AMGEN INC.

All filings by Empire Consulting Group · Everything Amgen Inc. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

HR 10628, Biosimilars Access and Affordability

Bills named in this filing 1

H.R. 10628
Biosimilars Access and Affordability Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.